4-Amino-1-methylpiperidine → N-{5-[(1-methylpiperidin-4-yl)amino][1,2,4]triazolo[1,5-a]pyridin-2-yl}nicotinamide
반응식
Br[C:2]1[N:7]2[N:8]=[C:9]([NH:11][C:12](=[O:19])[C:13]3[CH:18]=[CH:17][CH:16]=[N:15][CH:14]=3)[N:10]=[C:6]2[CH:5]=[CH:4][CH:3]=1.[NH2:20][CH:21]1[CH2:26][CH2:25][N:24]([CH3:27])[CH2:23][CH2:22]1>>[CH3:27][N:24]1[CH2:25][CH2:26][CH:21]([NH:20][C:2]2[N:7]3[N:8]=[C:9]([NH:11][C:12](=[O:19])[C:13]4[CH:18]=[CH:17][CH:16]=[N:15][CH:14]=4)[N:10]=[C:6]3[CH:5]=[CH:4][CH:3]=2)[CH2:22][CH2:23]1참가 물질
3
실험 절차
The title compound was prepared following procedure described for example 30 but starting from N-(5-bromo[1,2,4]triazolo[1,5-a]pyridin-2-yl)nicotinamide ((B2), 100 mg; 0.31 mmol; 1.0 eq.) and 4-amino-1-methyl-piperidine (1.0 mL) as a white powder (30 mg, 27%). 1H NMR (DMSO-d6) δ 11.25 (brs, 1H), 9.13 (d, J=1.9 Hz, 1H), 8.77 (dd, J=4.7, 1.7 Hz, 1H), 8.32 (dd, J=8.0, 2.0 Hz, 1H), 7.56 (dd, J=8.1, 4.7 Hz, 1H), 7.51 (t, J=8.3 Hz, 1H), 6.89 (d, J=7.9 Hz, 1H), 6.46 (d, J=8.3 Hz, 1H), 6.312 (d, J=7.5 Hz, 1H), 3.49 (m, 1H), 2.77 (m, 2H), 2.17 (s, 3H), 2.05 (m, 2H), 1.89 (m, 2H), 1.70 (m, 2H). HPLC, Rt: 1.07 min. (purity 100.0%). LC/MS, M+(ESI): 352.4, M−(ESI): 350.4.